Osimertinib after surgery for early-stage EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older and able to sign consent before any study steps.
- You must have non-squamous non-small cell lung cancer that was confirmed by a central lab.
- Your scan results must show stage I before surgery, and your tumor must have an EGFR mutation (Ex19del or L858R).
- Your cancer must be completely removed by surgery with negative margins (no cancer seen at the cut edges).
- You must start osimertinib within 10 weeks after your operation, and you must have a strong enough overall health status (WHO 0–1).
- You must not have had other cancer treatments before joining, and you must not have certain lung, heart, liver/kidney, infection, or absorption problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests if taking osimertinib before surgery can help treat a type of non-small cell lung cancer that has specific EGFR mutations. It aims to understand how the cancer may become resistant to this targeted therapy.
This study tests whether a targeted therapy pill called osimertinib can help people whose lung cancer has returned after they already received targeted therapy following surgery. The goal is to see if this treatment can control the cancer and improve outcomes.
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
Hear when a new NSCLC, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.